Dr. Rawizza is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Brigham and Women's Hospital
75 Francis Street
Boston, MA 02115Phone+1 617-432-4686
Education & Training
- Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 2005 - 2008
- Duke University HospitalResidency, Internal Medicine/Pediatrics, 2001 - 2005
- Vanderbilt University School of MedicineClass of 2001
Certifications & Licensure
- MA State Medical License 2007 - 2026
- NC State Medical License 2001 - 2005
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin Start of enrollment: 2023 Jul 07
Roles: Principal Investigator, Contact
- Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention Start of enrollment: 2024 May 01
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Population pharmacokinetics of rifabutin among HIV/TB co-infected children on lopinavir/ritonavir-based antiretroviral therapy.Manna Semere Gebreyesus, Roeland E Wasmann, Helen McIlleron, Regina Oladokun, Prosper Okonkwo
Antimicrobial Agents and Chemotherapy. 2024-08-07 - Pretreatment and Acquired Drug Resistance in Children With Human Immunodeficiency Virus Type 1 in Jos, Nigeria.Augustine O Ebonyi, Jonathan Okpokwu, Holly Rawizza, Philippe Chebu, Beth Chaplin
Open Forum Infectious Diseases. 2024-03-01 - Timeliness of Point-of-Care Viral Load Results Improves Human Immunodeficiency Virus Monitoring in Nigeria.Beth Chaplin, Oche Agbaji, Harry Reyes Nieva, Bola Olatunde, Charlotte Chang
Clinical Infectious Diseases. 2023-02-08
Press Mentions
- Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB PreventionFebruary 29th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: